Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More
Zacks Investment Research | Nov 16, 2021 10:29PM ET
It has been a busy week for the biotech sector with drug approvals and other regular pipeline updates. The development of coronavirus treatments and subsequent progress also continue to be in the spotlight.
Recap of the Week’s Most Important Stories:
Regeneron (NASDAQ:REGN) Cocktail Gets EC Nod: Regeneron Pharmaceuticals surged after it entered into an advance purchase agreement with the EC. Per the agreement, Valneva would supply up to 60 million doses of VLA2001, its inactivated COVID-19 vaccine candidate, over two years, including approximately 27 million doses in 2022.
Additionally, the EC has the option to increase its initial purchase, in 2022, of VLA2001 up to a total of 60 million doses by the end of 2023. The agreement is under final review, including volumes required, by each of the EU member states. The delivery of the vaccine is currently expected to begin in April 2022.
Performance
Medical - Biomedical and Genetics Industry 5YR % Return
Biotech Stock Roundup: REGN, MRNA Post Q3 Earnings, SAVA Gains on AD Review Data ).
What's Next in Biotech?
Stay tuned for more pipeline, and regulatory updates.
Zacks’ Top Picks to Cash in on Artificial Intelligence
This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.
See 6 Artificial Intelligence Stocks With Extreme Upside Potential>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.